Tahmina Nasrin Poly1,2, Md Mohaimenul Rubel Islam1,2, Hsuan-Chia Yang2, Yu-Chuan Jack Li3,4,5,6. 1. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing Street, Taipei, 110, Taiwan. 2. International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan. 3. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing Street, Taipei, 110, Taiwan. jack@tmu.edu.tw. 4. International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan. jack@tmu.edu.tw. 5. Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan. jack@tmu.edu.tw. 6. TMU Research Center of Cancer Translational Medicine, Taipei, Taiwan. jack@tmu.edu.tw.
Abstract
PURPOSE: Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between NSAID use and PD risk in the elderly population. METHODS: The electronic databases such as PubMed, EMBASE, Scopus, Google Scholar, and Web of Science were used to search the relevant articles published between January 1990 and December 2017. Large (n ≥ 1000) observational design studies with a follow-up at least 1 year were considered. Two authors independently extracted information from the included studies. Random effect model was used to calculate risk ratios (RRs) with 95% confidence interval (Cl). RESULTS: A total of 17 studies with 2,498,258 participants and nearly 14,713 PD patients were included in the final analysis. The overall pooled RR of PD was 0.95 (95%CI 0.860-1.048) with significant heterogeneity (I2 = 63.093, Q = 43.352, p < 0.0001). In the subgroup analysis, the overall pooled RR of PD was 0.90 (95%CI 0.738-1.109), 0.96 (95%CI 0.882-1.055), and 0.99 (95%CI 0.841-0.982) from the studies of North America, Europe, and Asia. Additionally, long-term use, study design, individual NSAID use, and risk of PD were also evaluated. CONCLUSION: Despite the neuroprotective potential of NSAIDs demonstrated in some experimental studies, our findings suggest that there is no association between NSAIDs and the risk of Parkinson disease at the population level. Until further evidence is established, clinicians need to be vigilant ensuring that the use of NSAIDs remains restricted to their approved anti-inflammatory and analgesic effect.
PURPOSE: Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between NSAID use and PD risk in the elderly population. METHODS: The electronic databases such as PubMed, EMBASE, Scopus, Google Scholar, and Web of Science were used to search the relevant articles published between January 1990 and December 2017. Large (n ≥ 1000) observational design studies with a follow-up at least 1 year were considered. Two authors independently extracted information from the included studies. Random effect model was used to calculate risk ratios (RRs) with 95% confidence interval (Cl). RESULTS: A total of 17 studies with 2,498,258 participants and nearly 14,713 PDpatients were included in the final analysis. The overall pooled RR of PD was 0.95 (95%CI 0.860-1.048) with significant heterogeneity (I2 = 63.093, Q = 43.352, p < 0.0001). In the subgroup analysis, the overall pooled RR of PD was 0.90 (95%CI 0.738-1.109), 0.96 (95%CI 0.882-1.055), and 0.99 (95%CI 0.841-0.982) from the studies of North America, Europe, and Asia. Additionally, long-term use, study design, individual NSAID use, and risk of PD were also evaluated. CONCLUSION: Despite the neuroprotective potential of NSAIDs demonstrated in some experimental studies, our findings suggest that there is no association between NSAIDs and the risk of Parkinson disease at the population level. Until further evidence is established, clinicians need to be vigilant ensuring that the use of NSAIDs remains restricted to their approved anti-inflammatory and analgesic effect.
Authors: Marta San Luciano; Caroline M Tanner; Cheryl Meng; Connie Marras; Samuel M Goldman; Anthony E Lang; Eduardo Tolosa; Birgitt Schüle; J William Langston; Alexis Brice; Jean-Christophe Corvol; Stefano Goldwurm; Christine Klein; Simone Brockman; Daniela Berg; Kathrin Brockmann; Joachim J Ferreira; Meriem Tazir; George D Mellick; Carolyn M Sue; Kazuko Hasegawa; Eng King Tan; Susan Bressman; Rachel Saunders-Pullman Journal: Mov Disord Date: 2020-07-14 Impact factor: 10.338
Authors: Tcs Costa; E Fernandez-Villalba; V Izura; A M Lucas-Ochoa; N J Menezes-Filho; R C Santana; M D de Oliveira; F M Araújo; C Estrada; Vda Silva; S L Costa; M T Herrero Journal: J Neuroimmune Pharmacol Date: 2020-06-21 Impact factor: 4.147
Authors: Irina N Gaisina; Dmitry M Hushpulian; Arsen M Gaisin; Eliot H Kazakov; Navneet Ammal Kaidery; Manuj Ahuja; Andrey A Poloznikov; Irina G Gazaryan; Gregory R J Thatcher; Bobby Thomas Journal: Neurochem Int Date: 2021-07-27 Impact factor: 4.297